Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: A dose-mediated deleterious effect

European Journal of Heart Failure

Volumn 5, Issue 3, 2003, Pages 271-279

  Meune, Christophe ^a,e   Mahé, Isabelle ^a   Mourad, Jean Jacques ^b   Cohen Solal, Alain ^c   Levy, Bernard ^a   Kevorkian, Jean Philippe ^a   Jondeau, Guillaume ^d   Habib, Aïda ^a   Lebret, Marilyne ^a   Knellwolf, Anne Laure ^a   Simoneau, Guy ^a   Caulin, Charles ^a   Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Hopital Saint Michel   (France)

^c BEAUJON HOSPITAL   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e Hospital Cochin ^*  (France)

Author keywords

Angiotensin converting enzyme inhibitors; Aspirin; Bradykinin; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; RAMIPRIL; SPIRONOLACTONE; THROMBOXANE B2;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN URINE LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; TONOMETRY; TREATMENT OUTCOME;

EID: 0041438857     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(03)00006-0     Document Type: Article

References (41)

1. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
2. The Collaborative Group on ACE Inhibitor Trials, Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
3. Antiplatelet trialists' collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Part I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patient. Br Med J 1994;308:81-106.
4. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-9.
5. Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharmacol Ther 2000;67:530-7.
6. Hall D, Zeitler H, Rudolf W. Counteraction of the vasodilatator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
7. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
8. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Study II (CONSENSUS II). Am J Cardiol 1997;79:115-9.
9. Katz SD, Radin M, Graves T, Hauck C, Block A, Lejemtel TH. Effect of aspirin and ifetrofiban on skeletal muscle blood flow in patients with congestive heart failure and treated with enalapril. J Am Coll Cardiol 1999;34(1):170-6.
10. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlodipine with enalapril. Circulation 1998;98:757-65.
11. Kelly R, Hayward C, Ganis J, Daley J, Avolio A, O'Rourke M. Noninvasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry. J Vasc Med Biol 1989;1:142-9.
12. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
13. Lellouche F, Fradin A, Fitzgerald G, Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990;40:297-310.
14. Pradelles P, Grassi J, Chabardes D, Guiso N. Enzyme immunoassays of adenosin cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate using acetylcholinesterase. Anal Chem 1989;61:447-53.
15. Pradelles P, Grassi J, Maclouf J. Enzymeimmunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985;57:1170-3.
16. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
17. Asmar RG, Topouchian JA, Benetos A, Sayegh FA, Mourad JJ, Safar ME. Non-invasive evaluation of arterial abnormalities in hypertensive patients. J Hypertens 1997;15(Suppl 2):S99-S107.
18. Chen CH, Ting CT, Nussbacher A, et al. Validation of carotid artery tonometry as a mean of estimating augmentation index of ascending aortic pressure. Hypertension 1996;27:168-75.
19. London GM, Pannier B, Vicaut E, et al. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 1996;14:1139-46.
20. Merillon JP, Fontenier G, Lerallut JF, et al. Aortic input impedance in heart failure: comparison with normal subjects and its change during vasodilatator therapy. Eur Heart J 1984;5:447-55.
21. Laskey WK, Kussmaul WG. Arterial wave reflection in heart failure. Circulation 1987;75:711-22.
22. O'Rourke MF, Kelly RP. Wave reflection in the systemic circulation and its implications in ventricular function. J Hypertens 1993;11:327-37.
23. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001;38:434-8.
24. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibitors and calcium channel blokade. Circulation 1994;90:2786-96.
25. O'Rourke MF. Mechanical principles. Arterial stiffness and wave reflection. Pathol Biol 1999;47:623-33.
26. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
27. Bhagat K, Collier J, Vallance P. Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Circulation 1995;92:2113-8.
28. Galatius S, Wroblewski H, Kastrup J. Does aspirin treatment influence vascular resistance an fluid filtration in patients with congestive heart failure? Heart 1999;81:330.
29. Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997;54(Suppl 5):23-30.
30. Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20:S68-S73.
31. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.
32. Weskler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-5.
33. Meune C, Mahé I, Mourad JJ, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.
34. Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens 2000;13:776-82.
35. Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998;18:1041-52.
36. Baur LHB, Schipperheyn JJ, Van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
37. Guazzi M, Marenzi G, Alimento M, Contini M, Agostini P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997;95:1930-6.
38. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000;35:1808-12.
39. Harjai KJ, Nunez E, Turgut T, Newman J. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. Am J Cardiol 2001;87:483-7.
40. Jones CG, Cleland JGF. Meeting report-LIDO, HOPE, MEXCON and WASH studies. Eur J Heart Failure 1999;1:425-31.
41. Aumégeat V, de Groote P, Meurice T, Millaire A, Ducloux G, Lablanche JM. Aspirin and angiotensin converting enzyme inhibitors in 445 patients with moderate congestive heart failure. J Am Coll Cardiol 1999;33:214A.